The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1720
January 20, 2025
View Complete Issue         Table of Contents 2019 
Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
January 20, 2025 (Issue: 1720)
Zenocutuzumab (Bizengri – Merus), a bispecific HER2- and HER3-directed antibody, has received accelerated approval from the FDA for treatment of advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) or pancreatic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
Article code: 1720e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.